XML 53 R34.htm IDEA: XBRL DOCUMENT v3.21.1
Selected Quarterly Financial Data (unaudited) (Tables)
12 Months Ended
Dec. 31, 2020
Quarterly Financial Information Disclosure [Abstract]  
Schedule of Selected Quarterly Financial Information

The following table contains selected quarterly financial information for 2020 and 2019. The Company believes that the following information reflects all normal recurring adjustments necessary for a fair statement of the information for the periods presented. The operating results for any quarter are not necessarily indicative of results for any future period.

 

 

 

Three Months Ended

 

 

 

March 31,

2020

 

 

June 30,

2020

 

 

September 30,

2020

 

 

December 31,

2020

 

Revenue

 

$

 

 

$

 

 

$

 

 

$

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

 

4,069

 

 

 

2,488

 

 

 

2,684

 

 

 

1,925

 

General and administrative

 

 

2,807

 

 

 

1,912

 

 

 

2,344

 

 

 

2,267

 

Total operating expenses

 

 

6,876

 

 

 

4,400

 

 

 

5,028

 

 

 

4,192

 

Loss from operations

 

 

(6,876

)

 

 

(4,400

)

 

 

(5,028

)

 

 

(4,192

)

Other income (expense), net

 

 

62

 

 

 

10

 

 

 

5

 

 

 

(738

)

Net loss

 

 

(6,814

)

 

 

(4,390

)

 

 

(5,023

)

 

 

(4,930

)

Net loss per share—basic and diluted

 

$

(0.24

)

 

$

(0.14

)

 

$

(0.13

)

 

$

(0.12

)

Weighted average common shares outstanding—

   basic and diluted

 

 

27,810,358

 

 

 

31,221,139

 

 

 

39,321,177

 

 

 

40,997,759

 

Comprehensive loss:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

$

(6,814

)

 

$

(4,390

)

 

$

(5,023

)

 

$

(4,930

)

Other comprehensive gain (loss):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Unrealized gain (loss) on investments, net of tax of $0

 

 

(8

)

 

 

(1

)

 

 

1

 

 

 

(1

)

Total other comprehensive gain (loss)

 

 

(8

)

 

 

(1

)

 

 

1

 

 

 

(1

)

Total comprehensive loss

 

$

(6,822

)

 

$

(4,391

)

 

$

(5,022

)

 

$

(4,931

)

 

 

 

 

Three Months Ended

 

 

 

March 31,

2019

 

 

June 30,

2019

 

 

September 30,

2019

 

 

December 31,

2019

 

Revenue

 

$

 

 

$

 

 

$

 

 

$

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

 

4,174

 

 

 

4,305

 

 

 

4,475

 

 

 

4,709

 

General and administrative

 

 

3,139

 

 

 

3,075

 

 

 

3,440

 

 

 

2,639

 

Total operating expenses

 

 

7,313

 

 

 

7,380

 

 

 

7,915

 

 

 

7,348

 

Loss from operations

 

 

(7,313

)

 

 

(7,380

)

 

 

(7,915

)

 

 

(7,348

)

Other income (expense), net

 

 

101

 

 

 

208

 

 

 

166

 

 

 

112

 

Net loss

 

 

(7,212

)

 

 

(7,172

)

 

 

(7,749

)

 

 

(7,236

)

Net loss per share attributable to common stockholders—basic and diluted

 

$

(0.49

)

 

$

(0.26

)

 

$

(0.28

)

 

$

(0.26

)

Weighted average common shares outstanding—basic

   and diluted

 

 

14,816,253

 

 

 

27,526,065

 

 

 

27,810,358

 

 

 

27,810,358

 

Comprehensive loss:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

$

(7,212

)

 

$

(7,172

)

 

$

(7,749

)

 

$

(7,236

)

Other comprehensive loss:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Unrealized loss on investments, net of tax of $0

 

 

5

 

 

 

24

 

 

 

(7

)

 

 

(10

)

Total other comprehensive loss

 

 

5

 

 

 

24

 

 

 

(7

)

 

 

(10

)

Total comprehensive loss

 

$

(7,207

)

 

$

(7,148

)

 

$

(7,756

)

 

$

(7,246

)